Printer Friendly

ICVBM launches coronary gene therapy trial.

For the six million Americans waking up with angina every day, pain is a constant companion. Even the simplest tasks, such as getting up from a chair or climbing the stairs, can cause severe chest pain. Many of these patients have exhausted all conventional interventions and face limited futures. Fortunately, coronary gene therapy appears a promising option.

Readers may remember positive patient profiles from earlier coronary gene therapy trials at St. Elizabeth's Medical Center of Boston (which have as yet not resumed).

Now a trial is investigating the potential of a new and different gene protein to promote the growth of blood vessels to the heart. Called fibroblast growth factor IV (FGF4), the protein is entering Phase II/III testing at the Indiana Center for Vascular Biology and Medicine (ICVBM)/Krannert Institute of Cardiology.

Preliminary data demonstrate safety of the innovative gene therapy concept, as reported last April.

"There is no product approved to stimulate the growth of new blood vessels," noted Cindy Grines, M.D., lead author of the study that appeared in Circulation and director of the cardiac catheterization laboratories at William Beaumont Hospital in Royal Oak, Michigan. "We think the growth factor gene used here restarts this natural response. This is a completely new and different approach."

In July, ICVBM will begin enrolling patients in the Angiogenic GENe Therapy (AGENT 3) trial under the direction of Dr. Jeffrey Breall, director of cardiac catheterization and interventional cardiology for Krannert Institute of Cardiology, and Dr. Keith March, director of ICVBM. "The purpose of the trial is to facilitate formation of bypass vessels by accelerating a natural process called angiogenesis or collateral vessel formation," Dr. March explains. "Some people are able to grow vessels sufficiently on their own, but many do not. The idea of this trial is to use this adenoviral vector that has the great capability of transducing or sending genes into cells very well and efficiently. By carrying this gene vector into the coronary circulation, it should help the cells that form coronary blood vessels grow. For people with few or no conventional treatment options for angina, we hope this therapy will help grow bypass vessels and reduce chest pain."

Unlike studies at St. Elizabeth's, participants in the AGENT 3 trial could be candidates for other therapies.

"This trial serves a broader population," says Dr. Jeffrey Breall. "These people could potentially have an angioplasty, bypass, of other interventions, but if it seemed these may not be optimal therapy for the best long-term results, their physicians may deem them eligible for this trial."

Gene therapy has demonstrated great potential in stimulating the body's natural ability to grow new blood vessels--a process called angiogenesis--in oxygen-deprived areas of heart muscle damaged by coronary heart disease.

"FGF4 is a protein that causes the growth of blood vessels by stimulating both the endothelial and smooth muscle cells," Dr. March told Neighborhood Heart Watch. "It has been shown in preclinical and in Phase I and II patient studies that FGF4 helps the vessels to grow faster, decreases angina, and reduces ischemia."

Patients with stable class II-IV exertional angina due to coronary artery disease are eligible to participate in this multicenter, randomized, double-blind, placebo-controlled clinical trial.

If you would like to learn more about participating in the AGENT 3 trial at ICVBM, contact Julie Lacy, R.N., B.S.N., Clinical Research Coordinator, Indiana Center for Vascular Biology and Medicine, 975 West Walnut St., IB441, Indianapolis, IN 46202 or call 317-962-0138.

Patient Inclusion Criteria Include: * Age: 30-75 years old

* History of stable exertional angina (Class II to IV) due to coronary artery disease.

* Remain symptomatic despite treatment with anti-angina medications, but not requiring immediate intervention or revascularization.

Classes of Angina: * Class I-Angina pain with a lot of activity-including running or heavy lifting.

* Class II-Angina pain after about two blocks of walking or with a moderate amount of activity, but not really overt exercise.

* Class III-Chest pain after walking less than two blocks of one block at the regular rate.

* Class IV-Angina at rest, even while sitting in a chair or in bed

Editor: Keith L. March, M.D., Ph.D. Director, Indiana Center for Vascular Biology and Medicine

Research is the key to discovering better ways to care for patients and improve their quality of life. For information about making a tax-deductible gift, contact me at 317-278-0130, or e-mail: kmarch@iupui.edu
COPYRIGHT 2003 Curtis Magazine Group, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003 Gale, Cengage Learning. All rights reserved.

 
Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Neighborhood Heart Watch
Author:March, Keith L.
Publication:Indiana Business Magazine
Geographic Code:1USA
Date:Oct 1, 2003
Words:728
Previous Article:Eat well and lower your blood pressure.
Next Article:Bad breath could signal H. pylori infection.
Topics:


Related Articles
Glowing evidence of gene-altered arteries.
Genzyme Biosurgery, Excigen collaborate in developing gene therapy for cardiac arrhythmia.
ICVBM launches coronary gene therapy trial.
New approach for easing Angina.
Trials available for angina.
Jack Gardiner: patient number one.
New hope for chronic illnesses.
Gene trials for diabetic neuropathy.
Cardium wins patent dispute with Boston Scientific and Arch Development Corporation,.
Cardium wins patent dispute with Boston Scientific and Arch Development Corporation,.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters